Medical technology company Stryker (NYSE: SYK) fell short of the market’s revenue expectations in Q3 2026, but sales rose 7.6% year on year to $6.52 billion. Its non-GAAP profit of $3.52 per share was 0.8% below analysts’ consensus estimates.

Is now the time to buy SYK? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Stryker’s third quarter results were met with a negative market reaction, as the company’s revenue and non-GAAP profit both missed Wall Street expectations. Management attributed underperformance to a slowdown in the U.S. hip and knee replacement market, with CEO Kevin Lobo citing affordability pressures on patients, higher pre-authorization denials, and execution challenges from a recent SAP system implementation. Lobo described the quarter as “unusual,” highlighting that disruptions in commercial execution and external headwinds led to softer results, particularly in the Orthopaedics division.

Looking ahead, Stryker’s revised guidance reflects caution as management anticipates ongoing softness in elective procedures and supply constraints in peripheral vascular products. CFO Preston Wells emphasized the company’s focus on operational efficiency and margin management, while also noting, “We are continuing to assess market conditions, procedural volume trends, and a broader macroeconomic environment as we finalize forecasts for 2027.” Upcoming product launches, expanded robotics offerings, and the integration of recent acquisitions are expected to play a key role in driving future growth, but management stopped short of providing formal growth targets beyond this year.

Key insights from management’s remarks

Management pointed to a combination of market-driven and company-specific factors behind the quarter’s revenue shortfall and margin contraction, while highlighting resilience in MedSurg and Neurotechnology businesses.

• Orthopaedics market softness: The slowdown in hip and knee procedures was largely attributed to higher insurance deductibles, affordability concerns, and increased pre-authorization denials, delaying patient access to surgery. Management noted that these trends were particularly pronounced in the U.S., with additional pressure from regional disruptions in Europe and the Middle East.
• Commercial execution disruptions: Stryker’s Orthopaedics business faced execution challenges due to a recent SAP system transition and lingering effects from a cyber incident earlier in the year, which delayed order visibility and distracted sales teams. As a result, the company underperformed its historical share gains in joint replacement.
• MedSurg and Neurotechnology strength: Despite softness in Orthopaedics, MedSurg and Neurotechnology segments delivered strong growth, driven by demand for operating room infrastructure, sports medicine products, and robust capital equipment sales. Products like Sage, Smart Care, and endoscopy solutions showed double-digit growth.
• Peripheral vascular business recovery: The vascular segment benefited from a one-time revenue boost due to a regulatory milestone in China while ongoing supply disruptions continued to weigh on core results. Management expects inventory normalization to continue through year-end, with new product launches anticipated to accelerate recovery.
• Strategic M&A and pipeline expansion: Stryker completed the acquisition of ZuriMED, expanding its sports medicine platform, and invested in CMR Surgical to bolster its presence in soft tissue robotics. Management highlighted these moves as central to long-term growth, with the upcoming Versius platform launch and other pipeline products positioned to support future share gains.

Drivers of future performance

Stryker’s outlook for the coming quarters is shaped by ongoing procedural weakness in orthopedics, margin pressures, and the expected ramp-up of new product launches.

• Orthopaedics headwinds persist: Management anticipates continued softness in hip and knee replacement volumes due to affordability challenges, delayed procedures, and market uncertainty. CEO Kevin Lobo cautioned that demand recovery is tied to broader economic cycles, and the timing of a rebound remains difficult to predict.
• Margin management and operational efficiency: Stryker is focused on offsetting sales shortfalls through expense discipline and operational improvements, including targeted manufacturing initiatives and supply chain optimization. CFO Preston Wells stated the company aims to expand gross margins year-over-year despite pressures in higher-margin orthopedic procedures.
• Product launches and innovation: The pipeline remains active, with upcoming launches such as the powered hip impactor, Sonopet 3 ultrasonic aspiration platform, and the Versius Plus soft tissue robotics system. Management expects these products to contribute incrementally to growth in 2027 and beyond, with particular emphasis on capitalizing on underpenetrated markets and cross-selling opportunities from recent acquisitions.

Catalysts in upcoming quarters

In the coming quarters, the StockStory analyst team will be tracking (1) signs of stabilization or recovery in U.S. hip and knee procedure volumes, (2) the launch and early adoption of new products such as the powered hip impactor and Sonopet 3, and (3) progress in restoring peripheral vascular supply and inventory levels. Additionally, we will watch for evidence that recent M&A, particularly the CMR Surgical partnership and ZuriMED acquisition, are contributing to growth and competitive positioning.

Stryker currently trades at $296.17, down from $311.75 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Stocks that trumped tariffs

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.